NexTel Medical Corp. (f/k/a Exousia Pro, Inc.) (OTCID: MAJI), a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems, announces that it has amended its previously announced acquisition of JumpstartRx and NuevistraMed to include the acquisition of Island 40 Group, the parent company of JumpstartRx and NuevistraMed, and its full subsidiary platform. The revised transaction significantly expands the scope of the original acquisition by bringing NexTel a broader portfolio of health, wellness, pharmaceutical, institutional, and revenue-generation assets designed to accelerate commercial growth across multiple high-opportunity markets.
Read the full article: NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform //
Source: https://www.globenewswire.com/news-release/2026/07/22/3331607/0/en/nextel-medical-corp-amends-previously-announced-acquisition-to-acquire-island-40-group-and-full-subsidiary-platform.html?_gl=1*ki90dg*_up*MQ..*_ga*MTI0OTc5OTk3MC4xNzg0NzU0NDI2*_ga_ERWPGTJ5X8*czE3ODQ3NTQ0MjYkbzEkZzAkdDE3ODQ3NTQ0MjYkajYwJGwwJGgw*_ga_B6167QB2TF*czE3ODQ3NTQ0MjYkbzEkZzAkdDE3ODQ3NTQ0MjYkajYwJGwwJGgxNzc0MjI4ODY.